Transcriptional adaptation of pneumococci and human pharyngeal cells in the presence of a virus infection

Sheila Z Kimaro Mlacha1,2,6, Teresa C T Peret3, Nikhil Kumar2, Sandra Romero-Steiner4, Julie C Dunning Hotopp2, Nadeezha Ishmael2, Valerie Grinblat-Huse2, David R Riley2, Dean D Erdman3, George M Carlone4, Jacquelyn Sampson4, J Anthony G Scott1,5 and Hervé Tettelin2*

Abstract

Background: Viral upper respiratory tract infections are associated with increased colonization by Streptococcus pneumoniae but the mechanisms underlying this relationship are unclear. The objective of this study is to describe a comprehensive picture of the cellular interaction between the adhering bacteria and host cells in the presence or absence of a viral co-infection.

Results: Gene expression profiles of Detroit-562 pharyngeal cells, which were either mock-infected or infected with human respiratory syncytial virus (RSV) or human parainfluenza virus 3 (HPIV3), were analyzed using human microarrays. Transcription response of S. pneumoniae strain TIGR4 (serotype 4) in the presence of either mock- or viral-infected cells was analyzed by pneumococcal microarray. Significantly regulated genes were identified by both significance analysis of microarray (SAM) and a ≥2-fold change ratio cut-off. The adherence of S. pneumoniae to human pharyngeal cells was significantly augmented in the presence of RSV or HPIV3 infection. Global gene expression profiling of the host cells during infection with RSV or HPIV3 revealed increased transcription of carcinoembryonic antigen-related cell adhesion molecules (CEACAM1), CD47, fibronectin, interferon-stimulated genes and many other host cell adhesion molecules. Pneumococci increased transcription of several genes involved in adhesive functions (psaA, pilus islet), choline uptake and incorporation (lic operon), as well as transport and binding.

Conclusions: We have identified a core transcriptome that represents the basic machinery required for adherence of pneumococci to D562 cells infected or not infected with a virus. These bacterial genes and cell adhesion molecules can potentially be used to control pneumococcal adherence occurring secondary to a viral infection.

Keywords: Streptococcus pneumoniae, RSV, HPIV3, Gene expression, Microarray, Adherence, Bacterial-viral co-infection

Background

Viruses play a pivotal role in modulating host cells, consequently mediating bacterial superinfection [1-8]. However, the mechanisms responsible for promoting bacterial superinfection are poorly understood. There are two potential explanations: (a) the virus changes the structure of the respiratory tract, paving the way for bacterial pathogens [1,9-12]; or (b) the virus alters the host’s innate immune response, making it more susceptible to bacterial infections [13-17].

Although several studies have demonstrated suppression of the host’s immune response as a potential mechanism for bacterial superinfection, the degree of bacterial infection induced by prior viral infection is indistinguishable from that shown using experimental models without a complete immune system e.g. in vitro adhesion assays. This suggests separate or additional mechanisms of action that are independent of immune mechanisms. Studies of polymicrobial interactions have revealed that cellular receptors such as CD14, CD15, CD18, carcinoembryonic antigen-related cell adhesion molecule (CEACAM),
macrophage receptor (MARCO), platelet-activating factor (PAFR), fibronectin (FN) and fimbriae-associated receptors are likely to be involved in increased bacterial adherence after viral infection [9,11,14,18-21]. Given the diversity of host receptors, this list of adhesion molecules is unlikely to be exhaustive. Only a few studies have examined the local surface remodeling of human pharyngeal cells by viruses despite the fact that they are the portal of entry for both viruses and bacteria. The full range of adhesion molecules that can be up-regulated during a respiratory viral infection and facilitate bacterial attachment and entry is still unknown.

Some studies suggest that bacterial factors also play a part in this interaction, but whether or not bacteria modulate their surface structures to enhance adherence in the presence of viral infection remains controversial [19,22-24]. Several pneumococcal adhesins have been described [25-27] but their significance in virus-enhanced adherence has not been studied. PspA is the only pneumococcal virulence factor that has been shown to contribute to secondary pneumococcal infections after viral infection [22]. We sought to examine the genes expressed by Streptococcus pneumoniae when in contact with virus-infected cells in order to facilitate the design of vaccine and therapeutic targets to control bacterial adherence during polymicrobial infections. We used DNA microarrays to obtain a comprehensive view of: (a) the responses of human pharyngeal cells to infection with respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) and (b) the effect that the viral infection has on both attachment and gene regulation of the pneumococcus.

**Methods**

**Bacterial and viral strains and cell lines**

TIGR4 [28] and G54 [29] pneumococcal strains, respiratory syncytial virus (RSV) strain ch 93-18b and human parainfluenza virus 3 (HPIV3) strain C243 were used in this study. The RSV strain was originally obtained from the University of Rochester Medical Center and the HPIV3 strain originated from the CDC respiratory repository. Pharyngeal human carcinoma epithelial cells (Detroit 562, CCL138) were obtained from ATCC (Rockville, MD, USA) and were grown and maintained as previously described [26].

**Viral infection scheme and adherence assay**

Tissue culture microtiter plates were seeded with 200 μl of a 2 × 10^5 D562 cells/ml suspension per well and grown for ~4 d to about 80% confluence (9.6 × 10^7 cells/well). Semi-confluent monolayers were washed twice with phosphate buffered saline (PBS) and inoculated with a 100 μl volume of viral suspension. To infect monolayers with RSV, the virus stock containing 6.5 × 10^6 TCID_{50}/ml was diluted to 10^{-1} to 10^{-3} with minimal essential medium with Eagle's salts (EMEM) (Gibco Laboratories, Grand Island, NY, USA), supplemented with penicillin (50 μg/ml), streptomycin (50 μg/ml) and 2% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). Each dilution of the virus was inoculated in triplicate. For HPIV3, the virus stock containing 8.3 × 10^7 TCID_{50}/ml was diluted to 10^{-3} to 10^{-6} with serum-free EMEM containing penicillin (100 μg/ml), streptomycin (100 μg/ml) and supplemented with crystallized porcine trypsin. Each virus dilution was inoculated into six wells. The negative control, which constituted of the same culture medium used for viral inoculation but without the virus, was seeded in another six wells. Plates were incubated at 37°C in a 5% CO_2 incubator and, at 24 h intervals after inoculation (24–72 h for RSV and 24–120 h for HPIV3), were used for pneumococcal adherence experiments as previously described [26]. Briefly, monolayers were washed once with 125 μl/well of EMEM without L-glutamine and supplemented with 7% FBS (Atlas Biologicals, Fort Collins, CO). To the washed monolayer of each well, 80 μl of EMEM was added, followed by 20 μl/well of bacterial suspension (10^6 bacteria/well). The final D562 cell yield was 1.2 × 10^5 cells/well after 6 days of incubation resulting in an MOI of 0.01. Plates were incubated for 2 h at 37°C in a 5% CO_2 incubator to allow for adherence then washed 5 X with PBS with 0.2% bovine serum albumin (BSA) to remove non-adherent pneumococci. A 65 ml volume of Todd-Hewitt broth supplemented with 0.5% yeast extract (THYE), 0.8% agar, and 0.1% 2,3,5-triphenyl tetrazolium chloride (TTC; Difco Laboratories), was added and the plates were incubated overnight at 37°C in a 5% CO_2 incubator. The number of colonies of S. pneumoniae adhering to D562 cells was counted using an automated colony counter (Alphalmager; Alpha Innotech, CA). Adherence to both mock-infected cells (medium with no virus) and virus-infected cells was expressed as the mean (± standard error of the mean, SEM) number of colony forming units (CFUs) in at least 3 replicate wells. Differences in adherence between virus- and mock-infected cells were tested by Student’s t-test (p < 0.05). RSV or HPIV3 growth was detected and monitored by the use of an indirect immunofluorescence assay (Light Diagnostics Respiratory Viral Screen IFA, Millipore Corporation, Billerica, MA).

It is worth noting that although the adherence assays in this and in the accompanying manuscript by Kimaro Mlacha et al. were performed the same way, there was one difference in the treatment of mock-infected D562 cells (cells not infected with viruses) prior to the adherence assay. For this manuscript, the D562 cells were manipulated before reaching 100% confluence. At day 4, cells were washed to allow for viral inoculation. This manipulation of the monolayer might have resulted in fewer D562 cells...
being present at day 6 compared than those in the accompanying manuscript, which were left intact for 6 days. Despite this difference, the mock-infected and virus-infected cells within the assay described in this manuscript were treated exactly the same way, making the comparison relevant within this experiment.

For microarray experiments, semi-confluent D562 cells grown in tissue culture flasks were either mock-infected or infected with stock virus at $6.5 \times 10^5$ TCID$_{50}$/ml for RSV and $8.3 \times 10^3$ TCID$_{50}$/ml for HPIV3, and incubated at 37°C on a shaker. After 1 h of adsorption, fresh medium was added into each flask and cultures were incubated at 37°C for 3 d. The D562 cells were used for: (a) pneumococcal microarray experiments or (b) analysis of host-cell transcription profiles upon exposure to RSV or HPIV3. (a) Virus-infected and mock-infected cells were inoculated with 1 ml of pneumococcal TIGR4 strain containing $10^7$ bacteria and incubated for 2 h at 37°C in a 5% CO$_2$ incubator. Non-adherent bacteria (contained in the spent cell culture medium) were removed and cells were washed 3X with PBS and then treated immediately with 10 ml of RNAlater (Qiagen, Valencia, CA, USA). Adherent bacteria were dissociated from host cells by lysis with 0.1% (w/v) saponin in PBS followed by sonication using 5 s pulses for 1 min. Bacteria were subsequently harvested by differential centrifugation. Control bacteria, which were not exposed to host cells, were suspended in EMEM medium and then prepared in parallel and treated identically to adherent bacteria. Pellets were stored at −80°C. (b) After inoculation of semi-confluent D562 cells with viruses for 3 d, the viral suspension (or un-inoculated media for mock-infected controls) was removed from the monolayer and the cells were washed twice with PBS with 0.2% BSA. Subsets of the monolayers (both mock and virus-infected) were inoculated with 1 ml of pneumococcal TIGR4 strain suspension containing $10^7$ bacteria, and the remaining monolayers were mock-infected with EMEM. All monolayers were incubated for 2 h at 37°C in a 5% CO$_2$ incubator then washed 2X with PBS with 0.2% BSA. D562 cells were detached by treatment with 0.025% trypsin-EDTA (Gibco Laboratories, Grand Island, NY, USA), and cell clumps were disrupted by gently pipetting up and down. The cells were collected by centrifugation at 800 x g for 5 min and immediately placed into 5 vol of RNAlater (Ambion, Austin, TX, USA) to minimize RNA degradation. Samples were stored at 4°C overnight to allow RNAlater solution to thoroughly penetrate the cells. The supernatant was then removed and the pellet was stored at −80°C until further processing.

RNA preparation
Total RNA was isolated from: (a) RNA-stabilized bacteria adherent to either mock- or virus-infected D562 cells and bacteria growing freely in EMEM and (b) monolayers of D562 cells either mock-infected or infected with RSV or HPIV3. RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) in a lysing matrix containing silica beads on a FastPrep Instrument (MP Biomedicals, Solon, OH, USA) according to the manufacturer’s protocol. RNA was purified with the RNasy Mini Kit (Qiagen, Valencia, CA, USA) and the quality was assessed using the prokaryote and eukaryote total RNA chips on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

Microarray experiments
Bacterial microarray experiments were performed on version 6 S. pneumoniae DNA microarrays distributed by the Pathogen Functional Genomics Resource Center (PFGRC, J. Craig Venter Institute, Rockville, MD, USA) and consisted of 70-mer oligonucleotides representing open reading frames (ORFs) from the genomes of three strains: TIGR4, G54 and R6, as well as 10 amplicons and 500 70-mer oligonucleotides from Arabidopsis thaliana, which served as negative controls. The experiments were performed as previously described [30]. For analysis of the human host cell response, microarrays with PCR amplicons of 41,000 cDNA clones were used (kindly provided by Norman Lee at George Washington University, Washington, DC, USA). Preparation of labeled cDNA target and hybridization experiments were done as previously described [30] with the exception that for the human host cell response, the starting amount of RNA used to synthesize cDNA was 5 μg. Total RNA was isolated from 3 independent cultures (biological replicates) of TIGR4 strain and D562 cells. Dye-swap experiments (technical replicates) were also performed on each biological replicate.

Data normalization and analysis
Data were analyzed using the TM4 microarray software suite [31]. Spot intensities were quantified using Spotfinder v3.1.1. Normalization was performed using the iterative log mean centering algorithm implemented in the MIDAS software (v2.19), and the fluorescence ratios were calculated from the normalized values. Data from the independent replicate experiments (only where $n \geq 15$) were averaged using locally developed Perl scripts and the resultant averages used for clustering algorithms to check for similar patterns in gene expression. Hierarchical clustering (HCL) using average linkage and Euclidean distance was also performed on the data to check for variability across replicate slides. To determine whether the observed ratio changes in expression of genes were both statistically and biologically significant, we applied the double filter of: (a) a statistical test, significance analysis of microarrays (SAM) and (b) a threshold ratio of
relevant magnitude – a two-fold rise/fall in signal. For SAM analysis, a Δ value of 1.18 was used for TIGR4 in contact with mock-infected and Δ = 2.158 for TIGR4 in contact with viral-infected cells. This Δ cutoff corresponded to a false positive rate of 0%. We also included into the final analysis all statistically significant genes that did not meet the threshold value but appeared to be co-regulated with one of our identified genes as part of an operon. For analysis of the human host cell response to viruses, a less stringent fold change cut-off of 1.5 was used since the overall gene expression changes were generally lower on the human microarrays.

Validation of human microarray data by qRT-PCR
Reverse transcription was carried out using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions. Briefly, 1 μg of total RNA was incubated in gDNA Wipeout Buffer (7X) and RNase-free water and incubated at 42°C for 2 min to remove contaminating genomic DNA. The cDNA was synthesized from the RNA using Quantiscript reverse transcriptase (RT), Quantiscript RT buffer (5X), and a primer mix at 42°C for 15 min and then at 95°C for 3 min to inactivate the Quantiscript RT. Dilutions of the cDNA (0.25 μl of the above mixture per 20 μl reaction) were used as template in a reaction containing 2X QuantiTect SYBR Green mix (Qiagen, Valencia, CA, USA), RNase-free water and gene-specific primers (Additional file 1: Table S1). The qRT-PCR assays were conducted using an ABI 7900HT instrument (Applied Biosystems, Carlsbad, CA, USA). The reactions were denatured at 95°C for 15 min followed by amplification with 45 cycles of 94°C for 15 s, 55°C for 30 s and 72°C for 30 s. Data was analyzed using a comparative cycle threshold (ΔCt) method [32]. The ΔCt was normalized to a gene (NG_007992 - actin gene) that did not exhibit any significant change in expression as identified by the microarray experiments. Each sample was tested in triplicate. A similar procedure was used for qRT-PCR validation of pneumococcal microarray data. The primers used are listed in Additional file 1: Table S2.

Results
Effect of RSV and HPIV3 infection on the adherence of S. pneumoniae to human pharyngeal cells
D562 cells were permissive to infection with RSV and HPIV3, with discrete cytopathic effect (CPE) after 72 h but without much detachment of the monolayers hence allowing for pneumococcal adherence. We then investigated whether pneumococci adhered in greater numbers to virus-infected D562 cells than to mock-infected cells. The optimal incubation period of virus-infected cells required for maximum bacterial adherence was determined to be 72 h in a preliminary time-course experiment (data not shown). The adherence of pneumococcal strains TIGR4 and G54 to D562 cells increased significantly with prior viral infection (p < 0.05) (Figure 1). The degree of enhanced attachment ranged from 1.3- to 2-fold and was dependent on the dose of initial viral infection. Maximal adherence due to RSV infection was obtained at a viral titer of 6.5 × 10⁵ TCID₅₀/ml, and maximal adherence to HPIV3 was obtained at a viral titer of 8.3 × 10³ TCID₅₀/ml. This influence of viral dose on bacterial adherence was similar for both pneumococcal strains, although the strains varied markedly in their baseline adherence capacity without viral infection (Figure 1).

Gene expression patterns of S. pneumoniae in contact with either virus- or mock-infected human pharyngeal cells
To limit the number of variables being compared for the gene expression analysis, we restricted the experiments to one strain of pneumococcus, TIGR4, and one respiratory virus – HPIV3. RNA was isolated from TIGR4 in contact with HPIV3- or mock-infected D562 cells. Compared to controls (pneumococci in cell culture medium), the gene regulation ratios for pneumococci in contact with virus- or mock-infected pharyngeal cells varied from 0.1 to 14.4. Among the 77 genes that were up-regulated, 51 were regulated in both virus-infected and mock-infected conditions (Additional file 1: Table S3). These included genes involved in adhesive functions (psaA, pilus islet), choline uptake and incorporation (lic operon), transport and binding (SP_1855-SP_1857) and fatty acid metabolism (SP_0421-SP_0427). The most highly represented genes were those coding for hypothetical proteins (25%), some of which are putative membrane proteins. Of the 98 down-regulated pneumococcal genes, 62 were down-regulated in both virus-infected and mock-infected conditions and these included choline transporters (proWX, proV) and purine biosynthesis genes (pur operon) (Additional file 1: Table S3). Among these 51 up-regulated and 62 down-regulated genes, the degree of regulation was remarkably consistent in the two adherence conditions (Additional file 1: Figure S1). These genes underpin the common set of cell functions that are induced by exposure to pharyngeal cells – regardless of whether those cells are viral-infected.

Eight pneumococcal genes appeared in the list of genes that were up-regulated after contact with HPIV3-infected cells but were absent in the list of genes up-regulated after contact with mock-infected cells. These were: glnQ, a fibronectin-binding/glutamine transport gene, SP_0204-SP_0206, ribonucleotide reductase genes, SP_1428 and SP_2005, genes encoding hypothetical proteins, and SP_1765-SP_1767, glycosyl transferase genes. Upon further examination, we found that these genes were absent from the list of genes up-regulated by TIGR4 in contact with mock-infected cells because they did
not meet our criteria for inclusion in the analysis (see Methods). We used qRT-PCR to verify the expression levels of these genes in both conditions, adherence to HPIV3-infected and mock-infected cells. The 8 genes had comparable Ct values between the two conditions. Eighteen genes, all encoding hypothetical proteins, were up-regulated by TIGR4 in contact with mock-infected cells only. It is likely that the expression of these 18 genes is inhibited by the viral infection.

Effect of HPIV3 and RSV on the expression of human cell adhesion molecules
Given the very large number of human genes and the particular hypothesis under test in this study, we focused our analysis on genes encoding cell adhesion molecules. HPIV3 infection induced the up-regulation of 55 human genes (Table 1A). Four of these were also up-regulated in RSV-infected cells (Table 1 panels A and B, CD47, AADACL1, ZC3HAV1 and cIAP2, an apoptosis inhibitor). Other genes that were up-regulated by HPIV3-infected cells included interferon stimulated genes (ISGs), plasminogen activator urokinase (PLAU), collagen type XVII alpha 1, claudin 1, laminin alpha 3, matrix metallopeptidase 14, and molecules of the carcinoembryonic antigen-related cell adhesion molecules (CEACAM1). Infection with RSV induced the up-regulation of 20 genes, including proteins of the zinc finger family (ZNF23, ZNF318), protocadherin beta 19, Rho family GTPase 1, fibronectin type III domain containing protein, and caspase 10.

Since the results above suggested that the enhanced expression of various adhesion molecules following HPIV3 and RSV infection may increase the level of adherence of pneumococci, we sought to describe the transcription profiles of cell adhesion molecules exposed to the TIGR4 strain and compared them to the virus-induced transcription profiles. We found that genes that were regulated in the presence of HPIV3 and RSV were not significantly regulated in TIGR4; rather, infection with TIGR4 alone resulted in the up-regulation of a unique set of genes (Table 1C) which included selenium-binding protein 1 (SELENBP1), granulocyte colony stimulating factor receptor (CSF3R), and ADAM metallopeptidases. We also analyzed the transcription of host cells exposed to concurrent stimulation by both viral and bacterial pathogens and found that infection of D562 cells with HPIV3 or RSV followed by TIGR4 induced a similar response to that of infection with HPIV3 or RSV only (Table 1 panels A, B and C).

Confirmation of microarray results by qRT-PCR
A subset of differentially expressed genes from the human microarray experiments was selected and qRT-PCR analysis was undertaken to confirm the relative levels of gene expression. The experiments were performed on the same RNA samples used in microarray experiments. The correlation coefficient (R) between qRT-PCR and microarray results for pneumococcal transcription in contact with either virus-infected or mock-infected epithelial cells was
### Table 1 Differential expression of cell adhesion molecules

#### A. Genes up-regulated by infection with HPIV3

| GB#       | Gene name                                           | Gene symbol | HPIV3-infected/mock-infected | RSV-infected/mock-infected | TIGR4-infected/mock-infected | HPIV3-TIGR4-infected/mock-infected | RSV-TIGR4-infected/mock-infected | Fold change |
|-----------|-----------------------------------------------------|-------------|------------------------------|-----------------------------|-----------------------------|-----------------------------------|-----------------------------------|-------------|
| AA406020 | ISG15 ubiquitin-like modifier                       | ISG15       | 23.80                        | 1.10                        | 1.05                        | 24.76                             | 1.15                              |             |
| AA456886 | Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 | MX1         | 23.68                        | 1.11                        | 1.04                        | 16.12                             | 1.12                              |             |
| AA286908 | Myxovirus (influenza virus) resistance 2            | MX2         | 13.84                        | 1.06                        | 1.05                        | 12.35                             | 1.04                              |             |
| T95113    | Radical 5-adenosyl methionine domain containing 2   | RSAD2       | 11.72                        | 0.90                        | 1.11                        | 4.49                              | 1.39                              |             |
| AA126958 | DEAD (Asp-Glu-Ala-Asp) box polypeptide S8           | DDX58       | 11.55                        | 1.16                        | 0.88                        | 9.94                              | 0.96                              |             |
| AA419251 | Interferon induced transmembrane protein 1 (9-27)  | IFITM1      | 7.32                         | 0.96                        | 0.99                        | 5.88                              | 0.76                              |             |
| AA421603 | SAM domain and HD domain 1                          | SAMHD1      | 5.67                         | 0.96                        | 0.89                        | 4.80                              | 0.86                              |             |
| A245550  | Phospholipid scramblase 1                           | PLSCR1      | 5.00                         | 0.91                        | 0.95                        | 3.36                              | 1.11                              |             |
| AA905904 | TCF3 (E2A) fusion partner                           | TFPT        | 4.05                         | 1.35                        | 1.05                        | 4.12                              | 0.91                              |             |
| AA827287 | Interferon-induced protein 35                       | IFI35       | 3.85                         | 1.10                        | 0.95                        | 3.40                              | 1.00                              |             |
| H54259   | Tumor necrosis factor (ligand) superfamily, member 10 | TNFSF10   | 3.64                         | NA                          | 1.18                        | 4.32                              | NA                                |             |
| AA862371 | Interferon induced transmembrane protein 2 (1-8D)  | IFITM2      | 3.37                         | 0.85                        | 0.92                        | 2.18                              | 0.93                              |             |
| AA877255 | Interferon regulatory factor 7                       | IRF7        | 3.25                         | X                           | 1.06                        | 2.13                              | 0.71                              |             |
| R07870   | Baculoviral IAP repeat-containing 3; inhibitor of apoptosis protein | -           | 3.09                         | 2.09                        | 1.20                        | 1.79                              | 1.60                              |             |
| AA038270 | Eukaryotic translation initiation factor 2-alpha kinase 2 | EIF2AK2    | 2.91                         | 1.11                        | 0.99                        | 1.56                              | 1.04                              |             |
| AA479795 | Interferon stimulated exonuclease gene 20kda       | ISG20       | 2.91                         | NA                          | 1.10                        | 2.29                              | NA                                |             |
| N67034   | Interferon-induced protein 44-like                  | IFI44L      | 2.87                         | 1.01                        | 1.05                        | 2.90                              | 0.94                              |             |
| AA418724 | Zinc finger CCCH-type, antiviral 1                  | ZC3HAV1     | 2.82                         | 1.53                        | 1.31                        | 1.77                              | 1.49                              |             |
| N75384   | Peroxisome proliferator-activated receptor gamma, coactivator 1 beta | PPARGC1B | 2.45                         | 0.78                        | 0.94                        | NA                                | 0.58                              |             |
| W37864   | Phosphatase and tensin homolog                      | PTEN        | 2.43                         | 0.90                        | 0.93                        | 1.05                              | 0.78                              |             |
| H17861   | Ring finger protein 21                              | RNF213      | 2.26                         | 1.05                        | 1.03                        | 1.14                              | 1.02                              |             |
| AA983252 | Signal transducer and activator of transcription 2, 113kda | STAT2      | 2.23                         | X                           | 1.12                        | 1.53                              | NA                                |             |
| R70479   | Tumor necrosis factor, alpha-induced protein 3      | TNAIP3      | 2.17                         | 0.75                        | 1.03                        | NA                                | 0.73                              |             |
| AA128561 | Collagen, type XVII, alpha 1                        | COL17A1     | 1.95                         | 1.11                        | 1.99                        | 1.16                              | 1.15                              |             |
| A016022  | NLR family, CARD domain containing 5              | NLRCS5      | 1.93                         | X                           | X                           | NA                                | 0.94                              |             |
| N70463   | B-cell translocation gene 1, anti-proliferative     | BTG1        | 1.90                         | 1.43                        | 1.13                        | NA                                | 1.39                              |             |
| H61758   | ELK4, ETS-domain protein (SRF accessory protein 1) | ELK4        | 1.86                         | 0.80                        | 0.87                        | NA                                | 1.03                              |             |
| R33456   | Desmoplakin                                         | DSP         | 1.82                         | 1.03                        | 0.88                        | 1.18                              | 0.86                              |             |
| Accession | Description                                      | Symbol | Ratio (Infected/Uninfected) |
|-----------|--------------------------------------------------|--------|-----------------------------|
| AI085559  | Arylacetamide deacetylase-like 1                  | AADAACL1 | 1.80 1.64 X 1.69 1.79       |
| AA609992  | Dehydrogenase/reductase (SDR family) member 9    | DHR59  | 1.78 1.45 0.95 1.09 1.50    |
| AA136060  | Polycomb group ring finger 5                     | PCGF5  | 1.74 0.99 0.96 1.21 0.82    |
| AI364513  | Scavenger receptor class B, member 2              | SCARB2 | 1.72 1.06 NA NA 0.97       |
| AA491191  | Interferon, gamma-inducible protein 16            | IFI16  | 1.72 1.38 0.94 0.97 1.99    |
| AA451844  | Microtubule associated monooxygenase, calponin and LIM domain containing 2 | MICAL2 | 1.70 0.91 0.91 X 0.79    |
| R92801    | CD47 molecule                                    | CD47   | 1.68 1.57 1.01 1.16 1.64    |
| R93911    | Glycogen synthase kinase 3 beta                  | GSK3B  | 1.68 1.29 NA NA 1.32       |
| AA776304  | Pleckstrin 2                                      | PLEK2  | 1.67 0.97 NA 1.81 1.08     |
| AA490894  | Endoplasmic reticulum aminopeptidase 1           | ERP1   | 1.67 1.19 0.87 X 1.25       |
| AA777854  | Ring finger protein 12                            | RNF12  | 1.67 0.85 0.99 NA 0.92      |
| AA040699  | ELK3, ETS-domain protein (SRF accessory protein 2) | ELK3  | 1.65 0.99 0.91 X 0.86       |
| H95362    | Claudin 1                                         | CLDN1  | 1.64 0.83 NA 1.26 1.20      |
| AA411757  | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CEACAM1 | 1.63 X NA 1.41 0.51       |
| AA284668  | Plasminogen activator, urokinase                 | PLAU   | 1.63 1.15 1.27 X 1.25       |
| AA135422  | CCR4-NOT transcription complex, subunit 1        | CNOT1  | 1.63 0.99 0.89 1.04 1.05    |
| AA049712  | Epidermal growth factor receptor                 | EGFR   | 1.62 1.00 0.91 1.13 0.96    |
| N70848    | Ring finger protein 141                          | RNF141 | 1.58 1.11 0.94 1.08 0.90    |
| AA005112  | LIM domain 7                                      | LMO7   | 1.58 0.89 0.83 0.81 0.77    |
| AA488674  | Myeloid cell leukemia sequence 1 (BCL2-related)   | MCL1   | 1.58 0.96 X X 0.84         |
| AA018412  | Coiled-coil domain containing 93                 | CCDC93 | 1.57 0.92 1.11 1.03 0.85    |
| AA478738  | Catenin, beta interacting protein 1               | CTNNBIP1 | 1.55 0.97 0.88 X 1.03       |
| A652954   | Transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase) | TGM1  | 1.54 0.67 0.86 1.05 0.56    |
| N59721    | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 | SERPINE2 | 1.54 0.69 0.88 X 0.93       |
| AA001432  | Laminin, alpha 3                                 | LAMA3  | 1.53 1.23 0.86 0.94 1.21    |
| AA706099  | NEDD4 binding protein 1                          | N4BP1  | 1.52 1.08 1.01 1.19 0.98    |
| N33214    | Matrix metalloproteinase 14 (membrane-inserted)   | MMP14  | 1.52 0.84 0.79 1.26 0.91    |

**B. Genes up-regulated by infection with RSV**

| Accession | Description                                      | Symbol | Ratio (Infected/Uninfected) |
|-----------|--------------------------------------------------|--------|-----------------------------|
| AA406373  | Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) | TAP2  | 1.46 2.28 1.10 1.18 1.27 |
| AA620877  | Protein tyrosine phosphatase, receptor type, M    | PTPRM  | X 2.11 1.10 1.18 1.27       |
| Accession | Gene Name and Description                   | Expression Values |
|-----------|---------------------------------------------|-------------------|
| R07870    | Hypothetical protein LOC92270               | LOC92270          |
| AA001983  | Hypothetical LOC92482                       | LOC92482          |
| A014782   | Trinucleotide repeat containing 6B          | TNR6C6B           |
| H80712    | Caspase 10, apoptosis-related cysteine peptidase | CASP10         |
| H23077    | Rho family GTPase 1                         | RND1              |
| AA903644  | Potocadherin beta 19 pseudogene             | PCDHB19P          |
| A085559   | Arylacetamide deacetylase-like 1            | AADACL1           |
| H01197    | Pleckstrin homology domain containing, family F (with FYVE domain) member 2 | PLEKHF2          |
| R36431    | Fibronectin type III domain containing 3A   | FNDC3A            |
| AA047413  | Zinc finger protein 23 (KOX 16)             | ZNF23             |
| AA003552  | Lysozyme-like 1, lysozyme-like 2            | LYZL1, LYZL2      |
| AA485438  | Ring finger protein 187                     | RNF187            |
| R92801    | CD47 molecule                               | CD47              |
| A168153   | Pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 8 | PLEKHA8          |
| AA878257  | Colony stimulating factor 1                 | CSF1              |
| AA418724  | Zinc finger CCCH-type, antiviral 1          | ZC3HAV1           |
| A100484   | Zinc finger protein 318                     | ZNF318            |

**C. Genes up-regulated by infection with TIGR4**

| Accession | Gene Name and Description                   | Expression Values |
|-----------|---------------------------------------------|-------------------|
| T65736    | Selenium-binding protein                    | SELENBP1          |
| A093729   | ADAM metallopeptidase with thrombospondin type 1 motif, 2 | ADAMTS2          |
| A443000   | Granulocyte colony stimulating factor receptor | CSF3R            |
| A460304   | Human ribosomal DNA complete repeating unit  | CRISPLD2          |
| A003033   | Neural cell adhesion molecule 2             | NCAM2             |
| A094923   | HNF1 homeobox B                             | HNF1B             |
| A521362   | CR2/CD21/36d/Epstein-Barr virus receptor complement component receptor 2 | CR2              |
| T98262    | General transcription factor III, polypeptide 3 | GTF3C3           |
| A004604   | RIKEN                                       | LOC143678         |
| A188215   | Neuregulin 1                                | NRG1              |
| Gene Symbol | Gene Name                                      | Log2 Fold Change | p-Value | Log2 Fold Change | p-Value | Log2 Fold Change | p-Value | Log2 Fold Change | p-Value | Log2 Fold Change | p-Value |
|-------------|-----------------------------------------------|------------------|---------|------------------|---------|------------------|---------|------------------|---------|------------------|---------|
| W60968      | Myelin protein zero-like protein 2; Epithelial V-like antigen 1 precursor | MPZL2            | 2.19    | NA               | 2.47    | NA               | 0.36    |      |                   |         |                   |         |
| R88767      | Protocadherin 10; protocadherin 20 precursor  | PCDH20           | 2.13    | 0.72             | 1.34    | NA               | 0.81    |      |                   |         |                   |         |
| R01281      | Src kinase-associated phosphoprotein 1; SKAP55 protein | SKAP55           | 1.94    | NA               | 1.22    | NA               | 1.17    |      |                   |         |                   |         |
| AA150694    | LY6/PLAUR domain containing 6                | LYPD6            | 1.85    | NA               | 1.26    | NA               | 1.08    |      |                   |         |                   |         |
| AA707615    | Chromosome 9 open reading frame 116         | C9orf116         | 1.83    | 0.73             | 1.05    | NA               | 0.87    |      |                   |         |                   |         |
| H57180      | Phospholipase C-like phospholipase C, gamma 2 (phosphatidylinositol-specific) | PLCG2            | 1.82    | NA               | 1.23    | NA               | 1.09    |      |                   |         |                   |         |
| AA883775    | Metallaproteinase-disintegrin                | ADAM30           | 1.80    | 0.32             | 1.19    | NA               | 2.26    |      |                   |         |                   |         |
| A361560     | Homeo box C9                                 | HOXC9            | 1.76    | 0.59             | 0.91    | 0.89             | 0.93    |      |                   |         |                   |         |
| A380234     | C1q(p) complement component C1q receptor     | CD93             | 1.76    | 0.55             | 0.56    | NA               | NA      |      |                   |         |                   |         |
| R6733       | Zinc finger protein                          | ZNF397           | 1.74    | NA               | 1.59    | NA               | 1.10    |      |                   |         |                   |         |
| R08109      | Alu subfamily J sequence contamination warning entry | ZNF398          | 1.70    | 1.02             | 0.96    | 0.81             | 1.05    |      |                   |         |                   |         |
| AA176413    | F-box protein Fbx20                          | FBX20            | 1.70    | 0.36             | 1.18    | 1.09             |         |      |                   |         |                   |         |
| H90292      | Procollagen type V alpha 2                   | SERPINA1         | 1.70    | 0.77             | 0.94    | 1.47             | 0.76    |      |                   |         |                   |         |
| AA680249    | Bactericidal/permeability-increasing protein | BPI              | 1.69    | 1.20             | 2.06    | 1.24             | NA      |      |                   |         |                   |         |
| R47555      | Intraflagellar transport protein 57 homolog  | ESRRBL1          | 1.68    | 1.35             | 1.28    | 0.97             | 1.05    |      |                   |         |                   |         |
| AA620742    | Xenotropic and polytropic retrovirus receptor | XPR1             | 1.67    | 1.37             | 0.87    | 0.82             | 1.00    |      |                   |         |                   |         |
| AA137073    | Integrin, beta-like 1 (with EGF-like repeat domains) | ITGB1           | 1.66    | 0.81             | 1.03    | 0.74             | 0.99    |      |                   |         |                   |         |
| T70368      | Integrin, beta 5                             | ITGB5            | 1.66    | 1.03             | 1.09    | 1.64             | 1.01    |      |                   |         |                   |         |
| R76099      | Toll-like receptor 3                          | TLR3             | 1.62    | 0.58             | 0.83    | NA               | 0.85    |      |                   |         |                   |         |
| H52352      | Complement factor properdin                  | CFP              | 1.62    | NA               | 1.54    | NA               | 0.54    |      |                   |         |                   |         |
| R08903      | Scavenger receptor class B, member 1          | SCARB1           | 1.59    | NA               | 1.01    | NA               | 0.73    |      |                   |         |                   |         |
| AA150507    | Interleukin 1, beta                           | IL1B             | 1.59    | 1.99             | 1.81    | 1.17             | 0.56    |      |                   |         |                   |         |
| T98612      | Alpha-1 type III collagen                     | COL3A1           | 1.57    | 1.74             | 0.83    | NA               | 1.06    |      |                   |         |                   |         |
| T52330      | Interleukin 6 receptor                        | IL6R             | 1.57    | 1.36             | 1.06    | 1.07             | 1.17    |      |                   |         |                   |         |
| AA106600    | Nuclear RNA export factor 3                   | NXF3             | 1.56    | 1.58             | 1.23    | 0.99             | 1.00    |      |                   |         |                   |         |
| AA176249    | Transforming growth factor, beta 2            | TGFBI             | 1.56    | 0.64             | 0.87    | NA               | 1.18    |      |                   |         |                   |         |
| R10099      | Stabilin-2                                    | STAB2            | 1.56    | 0.98             | 1.10    | 1.18             | 1.21    |      |                   |         |                   |         |
| N32241      | Zinc finger protein 160                       | ZNF160           | 1.55    | NA               | 1.10    | NA               | 1.06    |      |                   |         |                   |         |
| W914221     | Tumor necrosis factor receptor superfamily, member 19 | TNFRSF19      | 1.55    | 1.17             | 1.06    | 0.53             | 0.92    |      |                   |         |                   |         |
| H93115      | Ras association (ralgds/AF-6) and pleckstrin homology domains 1 | RAPH1           | 1.54    | 1.56             | 0.72    | 0.80             | NA      |      |                   |         |                   |         |
| AA455067    | Non-Ab component of amyloid peptide precursor | SNCA             | 1.54    | NA               | 1.14    | NA               | 0.93    |      |                   |         |                   |         |
| R69721      | Apo-2 ligand, TNF-related apoptosis inducing ligand TRAIL | TNFSF10      | 1.54    | NA               | 0.83    | NA               | 1.24    |      |                   |         |                   |         |

Table 1 Differential expression of cell adhesion molecules (Continued)
Table 1 Differential expression of cell adhesion molecules (Continued)

| Accession | Gene Name                                      | Description                                              | Expression A | Expression B | Expression C | Expression D |
|-----------|-----------------------------------------------|----------------------------------------------------------|--------------|--------------|--------------|--------------|
| AA456622  | Wiskott-Aldrich syndrome protein interacting protein | WIPF1                                                   | 1.54         | NA           | 1.16         | NA           | 1.00         |
| H74265    | Protein tyrosine phosphatase, receptor type, C | PTPRC                                                   | 1.53         | NA           | 1.15         | NA           | 1.20         |
| T68892    | Secreted apoptosis related protein 2           | SFRP1                                                   | 1.52         | NA           | 0.95         | 1.17         | 1.16         |
| AA780815  | Alpha-2 type VIII collagen                    | COL8A2                                                   | 1.50         | 0.98         | 1.14         | 1.43         | 0.83         |

Genes listed are up-regulated by infection with HPIV3 (A), RSV (B), and/or TIGR4 (C).
X indicates genes that did not meet the criteria established for microarray analysis (see Methods); NA indicates data points that had no single value.
viral infection. Mechanism for increased bacterial adherence following this NA-enhanced bacterial adherence is not the only facilitate pneumococcal adherence [38]. This suggests sialic acid on eukaryotic cells, unmasking receptors that to pharyngeal cells. Viral neuraminidase cleaves terminal negative (RSV) viruses enhanced binding of pneumococci both the neuraminidase (NA)-positive (HPIV3) and NA-viruses most commonly predisposing to secondary bac-

Discussion

Binding of pneumococci to virus-infected cells
In the present study, we have used a well-established model of adherence to demonstrate that infection of human pharyngeal cells with paramyxoviruses RSV or HPIV3 enhanced the adherence of S. pneumoniae strains TIGR4 and G54. While this finding is consistent with the results of other in vitro studies [21,33-35], this is the first report of RSV and HPIV3 increasing the in vitro adherence of S. pneumoniae to human pharyngeal cells (Detroit 562). The enhanced adherence of bacteria to virus-infected cells was consistent across both viruses and pneumococcal strains/serotypes evaluated. HPIV3 and RSV were used in this study as they are among the viruses most commonly predisposing to secondary bacterial infections [36,37]. The results also show that both the neuraminidase (NA)-positive (HPIV3) and NA-negative (RSV) viruses enhanced binding of pneumococci to pharyngeal cells. Viral neuraminidase cleaves terminal sialic acid on eukaryotic cells, unmasking receptors that facilitate pneumococcal adherence [38]. This suggests that NA-enhanced bacterial adherence is not the only mechanism for increased bacterial adherence following viral infection.

Mechanism of viral/bacterial synergy: a bacterial standpoint
We wanted to determine whether: (i) the pneumococcus is capable of detecting and responding to the host cell changes by expressing additional factors to complement newly expressed host cell receptors on the surface of viral-infected cells, or (ii) S. pneumoniae simply expresses the same baseline set of genes in response to contact with host cell regardless of the status of viral infection. In the latter case, the advantage of viral infection to pneumococcal adherence would be determined entirely by the viral effect on human cells. Our results demonstrate that there is a common set of pneumococcal genes that participate in the induction of adherence regardless of the presence of a virus. We believe that this study is the first to analyze the reciprocal response of S. pneumoniae to viral infection at a global transcriptome level.

As enhanced adherence was observed with both pneumococcal strains and with both viruses, we focused the pneumococcal microarray experiments on one strain–virus combination. We selected TIGR4 because it exhibited greater adherence to epithelial cells than G54, and we selected HPIV3 because it expresses NA. Our observation that multiple pneumococcal adhesins are regulated upon the binding of the bacterium to both mock- and virus-infected cells suggests that there is a common set of genes whose protein products represent good targets for designing interventions to prevent pneumococcal infection in the nasopharynx.

The up-regulated operon SP_0204–SP_0206 encodes a ribonucleoside triphosphate reductase (nrnG) and its activating protein (nrnG). This operon is active during anaerobic conditions [39,40] and in many bacterial species, the operon is up-regulated to enable bacteria to survive during oxidative stress [39]. The gene nrdG has been shown to be up-regulated in S. pneumoniae during infection of blood and meninges [41]. Human cells infected with viruses generate a large amount of inflammatory products and therefore up-regulation of this operon in the pneumococcus suggests the existence of oxygen tension. This is a plausible explanation of how the pneumococcus is able to resist this stressful environment and in the end confer the phenotype of enhanced adherence. McCullers and colleagues have proposed that fibrin and fibrinogen, deposited during the regenerative process following viral infection, may provide additional attachment sites for bacteria [2]. It was therefore interesting to observe that gltQ (SP_1242), a gene previously shown to be required for adherence to fibronectin by group B Streptococcus [42] was significantly up-regulated in TIGR4 in contact with virus-infected cells. It is possible that it might have a specific adhesive function in S. pneumoniae on contact with virus-infected epithelial cells.

Mechanism of viral/bacterial synergy: a host standpoint
We hypothesized that viral infection can enhance bacterial adhesion by increasing the expression of host cell receptors. Our study supported this contention by showing that a variety of epithelial cell receptors (CEACAM1, CD47, interferon-stimulated genes, among others) were up-regulated in response to HPIV3 and RSV infection. Other studies examining this question have either focused exclusively on the expression of a small number of cell adhesion receptors, or have studied non-human epithelial cells. CEACAM1 and CD47 have previously been identified in the host cell response to viral infection [21] and we have confirmed this observation with regard to HPIV3. CEACAM1 binds meningococcal and gonococcal opacity-associated (Opa) proteins and mediates internalization of the bacteria into several cell types in vitro [43]. It also binds to Haemophilus influenzae and Moraxella catarrhalis, which share their ecological niche with S. pneumoniae. Though the CEACAM-binding adhesins in S. pneumoniae are unknown, if they exist, the fact that CEACAM1 is one of a small number of genes up-regulated after viral infection suggests that this may be an area for future study. CD47, a gene encoding an integrin-associated protein, was up-regulated in response to infection by both
HPIV3 and RSV in our study. Expression of CD47 has previously been shown to render mice susceptible to *E. coli* K1 meningitis [44].

Interestingly, the gene encoding a fibronectin type III domain-containing protein was up-regulated by the host in response to both viruses (significantly in RSV and moderately in HPIV3). In our pneumococcal gene expression studies, a fibronectin-binding gene, *glnQ* was highly up-regulated in TIGR4 in contact with virus-infected cells. The symmetry of these observations suggests that virus-induced up-regulation of fibronectin type III induced a reciprocal response in *S. pneumoniae* in the form of up-regulation of a ligand to match the newly up-regulated host receptor. This is a specific hypothesis worth pursuing in future functional experiments.

Other genes that were significantly up-regulated in our study include several interferon-stimulated genes (ISGs) and the urokinase plasminogen activator (PLAU), which mediates a response to the inflammation induced by the virus. Induction of ISGs and NOD-like receptor family (Table 1) in our study is consistent with a recent finding that the cross-talk between Nod1/Nod2 receptors and type 1 IFNs induced during a viral infection, promoted lethality in mice superinfected with *E. coli* [45]. Up-regulation of genes encoding a matrix metalloproteinase, MMP14 and also caspase 10 may provide a mechanism by which the viruses induce lysis of the host cell components and, in the process, facilitate increased adherence and possibly invasion of bacteria.

**Conclusions**

In summary, we have shown that: (a) D562 cells were permissive to RSV and HPIV3; (b) these viruses augmented the adherence of *S. pneumoniae* to the host cells by a factor of 1.3-2.0; (c) infection with both RSV and HPIV3 enhanced the transcription of host cell adhesion molecules that facilitate or mediate bacterial adhesion in general; and (d) there is a core transcriptome (at least in the TIGR4 strain) that represents the basic machinery required for adherence of pneumococci to D562 cells regardless of whether the cell is infected with a virus or not. Further elucidation of these mechanisms is most likely to be obtained by specific inhibition of the expression of the host cell receptors or by bacterial gene knock-out experiments.

**Additional file**

Additional file 1: Table S1. is a table listing the primers used for qRT-PCR analysis of human genes. Table S2. is a table listing the primers used for qRT-PCR analysis of pneumococcal genes. Table S3. is a table listing genes commonly significantly regulated by TIGR4 in contact with either viral- or mock-infected human pharyngeal cells. Figure S1. is a figure depicting the correlation of the log2 ratios of TIGR4 adherent to mock-infected cells and to HIPV3-infected cells. Figure S2. is a figure showing graphs of qRT-PCR validation of human and pneumococcal microarray results.

**Abbreviations**

CEACAM: Carcinembryonic antigen-related cell adhesion molecule; CPE: Cytopathic effect; D562 cells: Detroit 562 cells; FN: Fibronectin; HCL: Hierarchical clustering; HPIV3: Human parainfluenza virus 3; ISGs: Interferon-stimulated genes; MARCO: Macrophage receptor; NA: Neuraminidase; PAFR: Platelet-activating factor; RSV: Respiratory syncytial virus; SAM: Significance analysis of microarrays.

**Competing interests**

JAGS reports receiving a grant from GlaxoSmithKline Biologicals (Anthony Scott, Kayla Laserson; $2,575,975; Oct 2010-Sep 2013) for a study entitled: ‘A phase IV multi-site observational epidemiology study to assess potential risk for adverse events following immunization that may be associated with misuse of a two-dose vial of 10-valent Pneumococcal Conjugate Vaccine (Synflorix) in Kenya’.

**Authors’ contributions**

SZKM carried out the adherence assays and pneumococcal microarray experiments, analyzed the data and drafted the manuscript. TCTP participated in the design and performance of viral adherence assays. NK performed the human microarray experiments and qRT-PCR experiments. SRS participated in the design and performance of bacterial adherence assays and RNA extractions and drafting of the manuscript. JCDH participated in the design and analysis of all experiments involving molecular work in this manuscript. NI participated in the pneumococcal microarray experiments. VGH performed qRT-PCR experiments. DRR participated in the bioinformatics analysis of microarray work. DDE, GMC, JS participated in the design of the study. JAGS and HT conceived the study, participated in the study design and development, analysis and drafting of the manuscript. All authors read and approved this manuscript.

**Acknowledgements**

This work was supported by grants from the Wellcome Trust to Prof. Anthony Scott (081835) and University of Maryland internal funds to Dr. Hervé Tetteh. The authors wish to thank Dr. Norman Lee (George Washington University, Washington DC, USA) and the Pathogen Functional Genomics Resource Center (PfGRC) at the J. Craig Venter Institute (JCVI, Rockville, MD, USA) for providing microarray slides, Gowrisankar Rajam (Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA) for technical assistance and Margaret Mackinnon and Gregg Fegan (KEMRI/Wellcome Trust, Kilifi, Kenya) for expert advice on statistical methods.

**Author details**

1. Kenya Medical Research Institute – Wellcome Trust Research Programme, Kilifi, Kenya. 2. Department of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA. 3. Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. 5. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. 6. Present address: Respiratory & Meningeal Pathogens Research Unit, University of the Witwatersrand/Medical Research Council, Johannesburg, South Africa.

Received: 10 October 2012 Accepted: 24 May 2013

Published: 7 June 2013

**References**

1. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hianne C: Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1980, 134:1040–1044.

2. McCullers JA: Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2005, 18:571–582.

3. Bundage JF: Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 2006, 6:303–312.

4. Memoli MJ, Moens DM, Taubenberger JK: Pandemic and seasonal influenza: therapeutic challenges. Drug Discov Today 2008, 13:90–95.
phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model.

5. Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic preparedness. J Infect Dis 2008, 198:962–970.

6. Diavatopoulos DA, Short KR, Price JT, Wilksch JJ, Brown LE, Briles DE, Strugnell RA, Wijburg OL: Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J 2010, 24:1799–1798.

7. McCallers JA, Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011, 16:123–135.

8. McCallers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B: Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 2010, 202:1287–1295.

9. Seki M, Kosi K, Hara A, Inamura Y, Nakamura S, Kunihara S, Izumikawa K, Kakeya H, Yanamuro Y, Yanagihara K, et al Expression and DNA microarray analysis of a platelet activating factor-related molecule in severe pneumonia in mice due to influenza virus and bacterial co-infection. Jpn J Infect Dis 2009, 62:65–10.

10. Wang Q, Nagarkar DR, Bowman ER, Schneider D, Gosangi B, Lei J, Zhao Y, McCartney C, Burge J, Miller OJ, et al Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway cellular responses. J Immunol 2009, 183:6989–6997.

11. Hament JM, Kimpen JL, Fleer A, Wolfs TF: Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011, 16:123–135.

12. Morens DM, Taubenberger JK, Fauci AS: Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011, 16:123–135.

13. McNamee LA, Harmsen AG: Coinfection Is Associated with Loss of Murine Lung Repair Responses. J Infect Dis 2011, 203:113–114.

14. Livak KJ, Schmittgen TD: Real-time quantitative PCR and the 2(−Delta Delta Ct) Method. Methods 2001, 25:402–408.

15. Selinger DS, Reed WP: Pneumococcal adherence to human epithelial cells. Infect Immun 1979, 23:545–548.

16. Avadhanula V, Rodriguez CA, Devincenzo JP, Wang Y, Webby RJ, Ulett GC, Li Q, Kuestner RE, Ozinsky A, Strugnell RA, Wijburg OL: Pneumococcal adherence to human epithelial cells by anti-PsaA antibodies. Clin Diagn Lab Immunol 2003, 10:246–251.

17. Avadhanula V, Wang Y, Porter N, Adderson E: Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein. J Med Microbiol 2007, 56:1133–1137.

18. Techaaseni B, Techaaseni C, Mejias A, McCracken GH Jr, Ramilo O: Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J 2010, 29:516–523.

19. Hammitt LJ, Kazungu S, Morphet SC, Gibson DG, Mvula B, Trent AJ, Mwanuma S, Onyango CO, Betts A, Akech MT, et al: A preliminary study of pneumococcal etiology among hospitalized children in Kenya. Clin Infectious Diseases: an official publication of the Infectious Diseases Society of America 2012, 54(Suppl 2):S190–S199.

20. Hulten TL, McCullers JA: Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004, 23:S87–S97.

21. Kedis E, Jonsson P, Kabuki M, Potempa J, Josefsson E, Masalah M, Foster SJ, Tarkowski A: Ribonucleotide reductase class II, an essential enzyme for the anaerobic growth of Staphylococcus aureus, is a virulence determinant in septic microbe. Microb Pathogen 2007, 43:179–188.

22. Bottoni ME, Tara VS, Hend J, Andrew PW, Yeshaya K: The pneumococcal response to oxidative stress includes a role for Rgg. Microbiology 2009, 155:412–413.

23. Ohrueila CI, Radian IN, Sublette JG, Gaq G, Kausahl D, Tuemmanen EI: Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun 2004, 72:5582–5596.

24. Tarnura GS, Nittayiam P, Schoenstatt D: A glutamine transport gene, gltR, is required for fibronectin adherence and virulence of group B streptococci. Infect Immun 2002, 70:287–298.

25. Wang J, Gray-Owen SD, Knorre A, Meyer TF, Dehio C: Pneumococcal surface protein A contributes to oxidative stress includes a role for Rgg. Microbiology 2009, 155:412–413.

26. Mittal R, Gonzalez-Gomez J, Prasadavilavakul K: Prevention of CD47 with thrombospondin-1 to prevent the maturation
of dendritic cells in the pathogenesis of neonatal meningitis. J Immunol 2010, 185:2998–3006.

45. Kim YG, Park JH, Reimer T, Baker DP, Kawai T, Kumar H, Akira S, Wobus C, Nunez G: Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 2011, 9:496–507.

doi:10.1186/1471-2164-14-378

Cite this article as: Kimaro Mlacha et al.: Transcriptional adaptation of pneumococci and human pharyngeal cells in the presence of a virus infection. BMC Genomics 2013 14:378.